Amedisys Inc. (AMED)
NASDAQ: AMED
· Real-Time Price · USD
97.66
0.01 (0.01%)
At close: Jun 25, 2025, 11:01 AM
Amedisys Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High Acuity Care Revenue | 32M | 19M | 1.36B | 3.5M | 750.1M | 617.2M | 1.17B | 1.1B | 1.09B | 1.01B | 956.9M | 987.7M | 1.2B |
| High Acuity Care Revenue Growth | +68.42% | -98.60% | +38628.57% | -99.53% | +21.53% | -47.45% | +6.60% | +1.50% | +8.00% | +5.04% | -3.12% | -17.55% | n/a |
| Home Health Revenue | 1.49B | 1.4B | 18.5M | 1.35B | 1.25B | 1.26B | 410.9M | 371M | 316M | 275.4M | 247.6M | 261.6M | 289.9M |
| Home Health Revenue Growth | +6.19% | +7487.03% | -98.63% | +8.37% | -0.57% | +205.77% | +10.75% | +17.41% | +14.74% | +11.23% | -5.35% | -9.76% | n/a |
| Hospice Revenue | 825.8M | 798.8M | 787.8M | 791.8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Hospice Revenue Growth | +3.38% | +1.40% | -0.51% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 196.16M | 202.7M | 198.34M | 7.83M | 7.43M | 197.04M | 192.98M | 212.99M | 194.56M | 193.43M | 188.34M | 187.82M | 184.47M | 184.85M | 178.93M | 175.22M | 172.24M | 175.6M | 179.62M | 156.34M | 156.74M | 156.06M | 154.71M | 152.3M | 144.85M | 132.32M | 124.54M | 123.09M | 121.36M | 123.67M | 118.88M | 120.92M | 118.75M | 124.84M | 124.43M | 126.66M | 127.5M | 120.27M | 112.6M | 115.56M | 104.01M |
| Selling, General, and Administrative Revenue Growth | -3.23% | +2.20% | +2433.67% | +5.31% | -96.23% | +2.10% | -9.40% | +9.48% | +0.58% | +2.70% | +0.28% | +1.82% | -0.21% | +3.31% | +2.12% | +1.73% | -1.91% | -2.24% | +14.89% | -0.25% | +0.43% | +0.87% | +1.58% | +5.15% | +9.47% | +6.24% | +1.18% | +1.43% | -1.87% | +4.03% | -1.69% | +1.82% | -4.88% | +0.34% | -1.76% | -0.67% | +6.02% | +6.81% | -2.55% | +11.10% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | 3.8M | n/a | n/a | n/a | 3M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |